Kiniksa Pharmaceuticals (NASDAQ:KNSA) Coverage Initiated at Jefferies Financial Group

Jefferies Financial Group assumed coverage on shares of Kiniksa Pharmaceuticals (NASDAQ:KNSA) in a research note released on Friday morning, Marketbeat reports. The brokerage issued a buy rating and a $40.00 price objective on the stock.

Separately, Wedbush upped their price objective on Kiniksa Pharmaceuticals from $30.00 to $34.00 and gave the company an outperform rating in a report on Tuesday, July 23rd. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of Buy and an average target price of $33.60.

Kiniksa Pharmaceuticals Stock Performance

Kiniksa Pharmaceuticals stock opened at $25.16 on Friday. The company has a market cap of $1.78 billion, a P/E ratio of 228.73 and a beta of 0.33. Kiniksa Pharmaceuticals has a 1 year low of $14.12 and a 1 year high of $27.92. The firm’s 50-day moving average is $24.72 and its 200-day moving average is $21.08.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, July 23rd. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.03. Kiniksa Pharmaceuticals had a negative return on equity of 7.79% and a negative net margin of 3.10%. The company had revenue of $108.30 million for the quarter, compared to analysts’ expectations of $90.60 million. During the same quarter in the previous year, the company posted ($0.02) earnings per share. The business’s revenue for the quarter was up 51.5% compared to the same quarter last year. As a group, sell-side analysts predict that Kiniksa Pharmaceuticals will post -0.31 earnings per share for the current year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, CEO Sanj K. Patel sold 136,124 shares of Kiniksa Pharmaceuticals stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $25.65, for a total transaction of $3,491,580.60. Following the transaction, the chief executive officer now directly owns 63,012 shares in the company, valued at approximately $1,616,257.80. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In other Kiniksa Pharmaceuticals news, CEO Sanj K. Patel sold 136,124 shares of the stock in a transaction that occurred on Tuesday, July 23rd. The shares were sold at an average price of $25.65, for a total value of $3,491,580.60. Following the completion of the sale, the chief executive officer now owns 63,012 shares in the company, valued at approximately $1,616,257.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider John F. Paolini sold 22,000 shares of the company’s stock in a transaction dated Tuesday, July 23rd. The stock was sold at an average price of $26.32, for a total value of $579,040.00. Following the completion of the transaction, the insider now directly owns 47,803 shares in the company, valued at $1,258,174.96. The disclosure for this sale can be found here. In the last quarter, insiders have sold 260,564 shares of company stock worth $6,727,929. Company insiders own 54.57% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Essex Investment Management Co. LLC grew its stake in Kiniksa Pharmaceuticals by 0.5% in the 1st quarter. Essex Investment Management Co. LLC now owns 172,740 shares of the company’s stock valued at $3,408,000 after buying an additional 850 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Kiniksa Pharmaceuticals by 5.8% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 20,935 shares of the company’s stock valued at $413,000 after buying an additional 1,153 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of Kiniksa Pharmaceuticals by 8.1% in the first quarter. SG Americas Securities LLC now owns 19,160 shares of the company’s stock valued at $378,000 after buying an additional 1,435 shares during the period. QRG Capital Management Inc. grew its position in Kiniksa Pharmaceuticals by 11.7% during the fourth quarter. QRG Capital Management Inc. now owns 16,010 shares of the company’s stock worth $281,000 after buying an additional 1,679 shares in the last quarter. Finally, Linden Thomas Advisory Services LLC increased its stake in Kiniksa Pharmaceuticals by 1.7% during the second quarter. Linden Thomas Advisory Services LLC now owns 118,302 shares of the company’s stock valued at $2,209,000 after acquiring an additional 1,921 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.